Blindness News and Research RSS Feed - Blindness News and Research

UTHealth's Bhavani Iyer awarded grant to help Harris County residents with vision problems

UTHealth's Bhavani Iyer awarded grant to help Harris County residents with vision problems

Bhavani Iyer, O.D., a low vision specialist at The University of Texas Health Science Center at Houston Medical School, has been awarded a grant to help Harris County residents whose vision problems cannot be corrected with eyeglasses, medication or surgery. [More]
Asia's first genetic test developed for identifying patients with corneal stromal dystrophy

Asia's first genetic test developed for identifying patients with corneal stromal dystrophy

A team of eye doctors and scientists from Singapore have developed Asia's first genetic test for identifying patients with a type of eye disease that affects the cornea called corneal stromal dystrophy which can lead to blurring and loss of vision. [More]
Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapy now being offered at NHS hospital in the UK and at four prestigious university hospitals in Germany

Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye. [More]
Parents severely underestimate time children spend on digital devices

Parents severely underestimate time children spend on digital devices

According to the American Optometric Association (AOA), parents severely underestimate the time their children spend on digital devices. An AOA survey reports that 83 percent of children between the ages of 10 and 17 estimate they use an electronic device for three or more hours each day. [More]
Early stage AMD can occur much earlier than previously thought

Early stage AMD can occur much earlier than previously thought

It is widely accepted that age-related macular degeneration (AMD) is the most common cause of visual impairment and blindness in industrialized countries. [More]
Iodine supplement can reduce central foveal swelling in RP patients with CME

Iodine supplement can reduce central foveal swelling in RP patients with CME

Cystoid macular edema (CME) is a common complication of retinitis pigmentosa (RP), a family of retinal diseases in which patients typically lose night and side vision first and then develop impaired central vision. CME can also decrease central vision. [More]
Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation. [More]
Encapsula releases 2 new liposome based products

Encapsula releases 2 new liposome based products

Encapsula NanoSciences announces the release of two new liposome ­based products; Curcusome® and Taurosome™. Curcusome® or liposomal curcumin is a nutraceutical supplement that comes innovatively packaged in a powder ­release cap for consumer ease. [More]
Acute glaucoma is largely an inflammatory disease, say researchers

Acute glaucoma is largely an inflammatory disease, say researchers

Researchers at the University of California, San Diego School of Medicine and Sun Yat-sen University in China have shown that acute glaucoma in mice is largely an inflammatory disease and that high pressure in the eye causes vision loss by setting in motion an inflammatory response similar to that evoked by bacterial infections. [More]
Improving type 2 diabetes management: an interview with Sir Michael Hirst, President of the International Diabetes Federation

Improving type 2 diabetes management: an interview with Sir Michael Hirst, President of the International Diabetes Federation

One study suggested that 42 percent of people with type 2 diabetes who are treated for the disease do not reach their blood sugar goals, putting them at higher risk of organ and tissue damage, blindness and even death. We wanted to explore potential causes of clinical inertia among physicians and people with diabetes, which may lead to sub-optimal care. [More]
BrightFocus offers grants to 55 scientists for Alzheimer's disease and vision research

BrightFocus offers grants to 55 scientists for Alzheimer's disease and vision research

BrightFocus Foundation, a nonprofit organization funding cutting-edge, innovative research on Alzheimer's disease and the vision diseases of glaucoma and macular degeneration, today announced the recipients of new research grant awards, offered to 55 scientists in 19 U.S. states, the District of Columbia, and five foreign countries. [More]
New chemical compound protects against blindness and diabetes in animals

New chemical compound protects against blindness and diabetes in animals

In a new study led by UC San Francisco scientists, a chemical compound designed to precisely target part of a crucial cellular quality-control network provided significant protection, in rats and mice, against degenerative forms of blindness and diabetes. [More]
New approach for developing personalized gene therapies to treat retinitis pigmentosa

New approach for developing personalized gene therapies to treat retinitis pigmentosa

Columbia University Medical Center researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss. [More]
LA BioMed researchers launch new project to improve diabetes management

LA BioMed researchers launch new project to improve diabetes management

Managing diabetes is a year-round challenge for anyone living with the disease. The challenge is even greater for underserved and uninsured people who often don't have easy access to the care they need to manage their diabetes. [More]
Quantel Medical receives FDA clearance for Optimis Fusion integrated laser platform

Quantel Medical receives FDA clearance for Optimis Fusion integrated laser platform

Quantel Medical today announced FDA 510(k) clearance for its Optimis Fusion integrated laser platform. The Optimis Fusion system combines advanced selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional YAG photodisruption treatments to offer ophthalmologists a versatile armamentarium for treating both cataract and glaucoma in an efficient combination platform. [More]
Dental pulp stem cells can protect retinal ganglion cells from death following injury

Dental pulp stem cells can protect retinal ganglion cells from death following injury

Researchers at the University of Birmingham, UK, led by Dr. Ben Scheven, Dr. Wendy Leadbeater and Ben Mead have discovered that stem cells isolated from the teeth, termed dental pulp stem cells (DPSC), can protect retinal ganglion cells (RGCs) from death following injury and promote regeneration of their axons along the optic nerve. [More]
Researchers discover a way to restore corneal surface

Researchers discover a way to restore corneal surface

A Boston-based scientific collaborative, led by Harvard Stem Cell Institute researchers, has discovered a way to collect the best cell type for regenerating a damaged cornea-the clear membrane that covers the pupil and directs light into the back of the eye. [More]

Study results may help prevent eye injuries among soldiers

Researchers at The University of Texas at San Antonio are discovering that the current protective eyewear used by our U.S. armed forces might not be adequate to protect soldiers exposed to explosive blasts. [More]
BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight enrolls first patient in FDA Phase 1/2a clinical trial with Eye-D for treatment of glaucoma

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D, the company's controlled-release latanoprost insert for the treatment of glaucoma. [More]
Light-sensitive molecule enables noninvasive silencing of neurons

Light-sensitive molecule enables noninvasive silencing of neurons

Optogenetics, a technology that allows scientists to control brain activity by shining light on neurons, relies on light-sensitive proteins that can suppress or stimulate electrical signals within cells. This technique requires a light source to be implanted in the brain, where it can reach the cells to be controlled. [More]